Page 2

ne 4, 2007

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell,

comprising contacting said bcl-6-expressing cell with a composition that reduces an amount of said bcl-6 protein or of a ribonucleic acid molecule encoding said bcl-6

protein, thereby inducing apoptosis in a bcl-6-expressing cell, wherein said

composition comprises a molecule complementary to all or portion of the sequence set

forth in SEQ ID NO: 6.

2. (Original) The method of claim 1, wherein said cell is a lymphoma cell.

3. (Original) The method of claim 2, wherein said lymphoma cell is a non-Hodgkin's

lymphoma cell.

4. (Currently amended) A method of treating a subject with a lymphoma comprising a

bcl-6-expressing lymphoma cell, comprising contacting said subject with a

composition that reduces an amount of said bcl-6 protein or of a ribonucleic acid

molecule encoding said bel-6 protein, thereby treating a subject with cancer comprising a bel-6-expressing cell, wherein said composition comprises a molecule

complementary to all or portion of the sequence set forth in SEO ID NO; 6.

5. (Original) The method of claim 4, wherein said lymphoma is a non-Hodgkin's

lymphoma.

6. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell,

comprising contacting said bcl-6-expressing cell with a composition comprising a

nucleic acid molecule complementary to <u>all or portion of the sequence set forth in</u>
SEO ID NO: 6 a region of a ribonucleic acid molecule encoding said bel 6 protein.

thereby inducing apoptosis in a bcl-6-expressing cell.

7. (Original) The method of claim 6, wherein said cell is a lymphoma cell.

8. (Original) The method of claim 7, wherein said lymphoma cell is a non-Hodgkin's

2

Page 3

lymphoma cell.

 (Original) The method of claim 6, wherein said nucleic acid molecule is an oligodeoxyribonucleic acid (ODN) molecule.

(Canceled).

- 11. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a composition comprising a nucleic acid molecule complementary to <u>all or portion of the sequence set forth in SEO ID NO: 6 a region of a ribonucleic acid molecule encoding said bel-6 protein</u>, thereby treating a subject with cancer comprising a bcl-6-expressing cell.
- (Original) The method of claim 11, wherein said lymphoma is a non-Hodgkin's lymphoma.
- (Original) The method of claim 11, wherein said nucleic acid molecule is an oligodeoxyribonucleic acid (ODN) molecule.
- (Canceled).
- 15. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a composition comprising a nucleic acid molecule corresponding to all or portion of the sequence set forth in SEQ ID NO: 6 a region of a ribonucleic-acid molecule-encoding-said-bcl-6-protein, thereby inducing apoptosis in a bcl-6-expressing cell.
- (Original) The method of claim 15, wherein said cell is a lymphoma cell.
- (Original) The method of claim 16, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
- (Original) The method of claim 15, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.

Page 4

 (Original) The method of claim 15, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.

- (Canceled).
- 21. (Currently amended) A method of treating a subject with a lymphoma comprising a bel-6-expressing lymphoma cell, comprising contacting said subject with a composition comprising a nucleic acid molecule corresponding to all or portion of the sequence set forth in SEQ ID NO: 6 a region of a ribonucleic acid molecule encoding said bel-6-protein, thereby treating a subject with cancer comprising a bel-6-expressing cell.
- (Original) The method of claim 21, wherein said lymphoma is a non-Hodgkin's lymphoma.
- (Original) The method of claim 21, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.
- (Original) The method of claim 21, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.
- (Canceled).
- 26. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a vector expressing a nucleic acid molecule complementary to <u>all or portion of the sequence set forth in SEQ ID NO: 6 a region of a ribonucleic acid molecule encoding said bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.</u>
- 27. (Original) The method of claim 26, wherein said cell is a lymphoma cell.
- (Original) The method of claim 27, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
- 29. (Original) The method of claim 26, wherein said vector is a lentiviral vector.

Page 5

 (Original) The method of claim 26, wherein said nucleic acid molecule is an oligodeoxyribonucleic acid (ODN) molecule.

- (Canceled).
- 32. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a vector expressing a nucleic acid molecule complementary to all or portion of the sequence set forth in SEO ID NO: 6 a region of a ribonucleic acid molecule encoding said bel-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.
- (Original) The method of claim 32, wherein said lymphoma is a non-Hodgkin's lymphoma.
- 34. (Original) The method of claim 32, wherein said vector is a lentiviral vector.
- (Original) The method of claim 32, wherein said nucleic acid molecule is an oligodeoxyribonucleic acid (ODN) molecule.
- (Canceled).
- 37. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a vector expressing a nucleic acid molecule corresponding to all or portion of the sequence set forth in SEQ ID NO;
 6 a region of a ribonucleic acid molecule encoding said bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.
- 38. (Original) The method of claim 37, wherein said cell is a lymphoma cell.
- (Original) The method of claim 38, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.
- (Original) The method of claim 37, wherein said vector is a lentiviral vector.
- (Original) The method of claim 37, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.

Page 6

- (Original) The method of claim 37, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.
- (Canceled).
- 44. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a vector expressing a nucleic acid molecule corresponding to all or portion of the sequence set forth in SEO ID NO: 6 a region of a ribonucleic acid molecule encoding said bel-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.
- (Original) The method of claim 44, wherein said lymphoma is a non-Hodgkin's lymphoma.
- 46. (Original) The method of claim 44, wherein said vector is a lentiviral vector.
- (Original) The method of claim 44, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.
- (Original) The method of claim 44, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.
- 49. (Canceled).
- (Withdrawn) An isolated nucleic acid molecule having a sequence selected from the sequences set forth in SEQ ID No: 1-10.
- 51. (Withdrawn) An oligo-deoxyribonucleic acid (ODN) molecule having a sequence corresponding to the isolated nucleic acid molecule of claim 50 or a fragment thereof, wherein said fragment is about 21-23 nucleotide in length.
- (Withdrawn) A composition comprising the isolated nucleic acid molecule of claim
 50.
- 53. (Withdrawn) A vector comprising the isolated nucleic acid molecule of claim 50.

Page 7

- 54. (Withdrawn) A cell comprising the isolated nucleic acid molecule of claim 50.
- (Withdrawn) An isolated nucleic acid molecule having a sequence complementary to a sequence selected from the sequences set forth in SEQ ID No: 1-10.
- 56. (Withdrawn) A short interfering ribonucleic acid (siRNA) molecule having a sequence corresponding to a fragment of the isolated nucleic acid molecule of claim 55, wherein said fragment is about 21-23 nucleotide in length.
- 57. (Withdrawn) A short hairpin RNA (shRNA) molecule comprising a sequence corresponding to a fragment of the isolated nucleic acid molecule of claim 55, wherein said fragment is about 19-23 nucleotide in length.
- (Withdrawn) A composition comprising the isolated nucleic acid molecule of claim
 55.
- 59. (Withdrawn) A vector comprising the isolated nucleic acid molecule of claim 55.
- 60. (Withdrawn) A cell comprising the isolated nucleic acid molecule of claim 55.